Teva Pharmaceuticals announced the launch of an authorized generic of Victoza, in the United States. “By launching an authorized generic for Victoza, we are providing patients with type 2 diabetes another option for this important treatment,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva. “In addition to strengthening Teva’s diverse complex generics portfolio, we are providing the first generic GLP-1 product to the U.S. marketplace, demonstrating once again our ability to sustain a generics powerhouse.” Victoza had annual sales of $1.656 billion as of April 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Corcept Therapeutics weakness a buying opportunity, says Canaccord
- Teva sues Corcept over alleged mifepristone market monopoly, Reuters says
- Teva call volume above normal and directionally bullish
- Teva price target raised to $21 from $20 at Barclays
- Teva presents first real-world data from IMPACT-TD Registry study